Alnylam Pharmaceuticals Price Target Raised to 298.00
ALNY Stock | USD 253.74 0.39 0.15% |
Slightly above 61% of Alnylam Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Alnylam Pharmaceuticals suggests that many traders are alarmed. Alnylam Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Alnylam Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Alnylam |
Alnylam Pharmaceuticals had its price objective lifted by Raymond James from 275.00 to 298.00 in a research report report published on Friday morning, Benzinga reports. Raymond James currently has an outperform rating on the biopharmaceutical companys stock. A number of other equities analysts have also weighed in on the stock. Canaccord
Read at thelincolnianonline.com
Alnylam Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
39
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Alnylam Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Alnylam Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Alnylam Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Alnylam Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Alnylam Pharmaceuticals Historical Investor Sentiment
Investor biases related to Alnylam Pharmaceuticals' public news can be used to forecast risks associated with an investment in Alnylam. The trend in average sentiment can be used to explain how an investor holding Alnylam can time the market purely based on public headlines and social activities around Alnylam Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Alnylam Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Alnylam Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Alnylam Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals Fundamental Analysis
We analyze Alnylam Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Alnylam Pharmaceuticals is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Alnylam Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alnylam Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Alnylam Pharmaceuticals Related Equities
APLS | Apellis Pharmaceuticals | 4.63 | ||||
PRQR | ProQR Therapeutics | 4.63 | ||||
HALO | Halozyme Therapeutics | 1.42 | ||||
DAWN | Day One | 1.33 | ||||
WVE | Wave Life | 1.08 | ||||
INCY | Incyte | 0.87 | ||||
BMRN | Biomarin Pharmaceutical | 0.83 | ||||
BPMC | Blueprint Medicines | 0.50 | ||||
UTHR | United Therapeutics | 0.30 | ||||
KRYS | Krystal Biotech | 0.20 | ||||
AMLX | Amylyx Pharmaceuticals | 0.00 | ||||
RARE | Ultragenyx | 0.00 | ||||
MDGL | Madrigal Pharmaceuticals | 0.81 | ||||
EXEL | Exelixis | 1.43 |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.